The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress

Molecular Pharmacology

Volumn 67, Issue 6, 2005, Pages 1882-1891

  Traver, Sabine ^a   Salthun Lassalle, Bénédicte ^a   Marien, Marc ^b   Hirsch, Etienne C ^a   Colpaert, Francis ^b   Michel, Patrick P ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINESTERASE; ADRENERGIC RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE; CATECHOL; CHOLINE ACETYLTRANSFERASE; HYDROXYL RADICAL; IRON CHELATING AGENT; NERVE GROWTH FACTOR; NORADRENALIN; REACTIVE OXYGEN METABOLITE; NEUROPROTECTIVE AGENT;

4 AMINOBUTYRIC ACID RELEASE; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL PROTECTION; CHOLINERGIC ACTIVITY; CHOLINERGIC NERVE; CONTROLLED STUDY; CYTOCHEMISTRY; DRUG EFFICACY; EMBRYO; FENTON REACTION; IMMUNOCYTOCHEMISTRY; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NERVE CELL STIMULATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; NORADRENALIN RELEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; SEPTUM PELLUCIDUM; WISTAR RAT;

ANIMALS; CELLS, CULTURED; CHOLINE O-ACETYLTRANSFERASE; CHOLINERGIC FIBERS; DOSE-RESPONSE RELATIONSHIP, DRUG; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NOREPINEPHRINE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SEPTUM OF BRAIN;

EID: 21744440927     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.007864     Document Type: Article

References (40)

1. Andorn AC and Pappolla MA (2001) Catecholamines inhibit lipid peroxidation in young, aged and Alzheimer's disease brain. Free Radic Biol Med 31:315-320.
2. Berridge CW and Waterhouse BD (2003) The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Rev 42:33-84.
3. Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB, and Perry G (2004) Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. Alzheimers Dis 6:165-169.
4. Chopin P, Debeir T, Raisman-Vozari R, Colpaert FC, and Marien MR (2004) Protective effect of the alpha2-adrenoceptor antagonist, dexefaroxan, against spatial memory deficit induced by cortical devascularization in the adult rat. Exp Neurol 185:198-200.
5. Colpaert F (1994) Noradrenergic mechanisms in Parkinson's disease: a theory, in Noradrenergic Mechanisms in Parkinson's Disease (Briley M, Marien M, eds), pp 225-254, CRC Press, Boca Raton, FL.
6. Cribbs DH, Poon WW, Rissman RA, and Blurton-Jones M (2004) Caspase-mediated degeneration in Alzheimer's disease Am J Pathol 165:353-355.
7. Debeir T, Marien M, Chopin P, Martel JC, Colpaert F, and Raisman-Vozari R (2002) Protective effects of the alpha2-adrenoceptor antagonist, dexefaroxan, against degeneration of the basalocortical cholinergic system induced by cortical devascularization in the adult rat. Neuroscience 115:41-53.
8. Fort P, Khateb A, Pegna A, Mühlethaler M, and Jones BE (1995) Noradrenergic modulation of cholinergic nucleus basalis neurons demonstrated by in vitro pharmacologial and immunohistochemical evidence in the guinea pig brain. J Neurosci 7:1502-1511.
9. Galea E, Heneka MT, Dello Russo C, and Feinstein DL (2003) Intrinsic regulation of brain inflammatory responses. Cell Mol Neurobiol 23:625-635.
10. Goldstein LB (2000) Effects of amphetamines and small related molecules on recovery after stroke in animals and man. Neuropharmacology 39:852-859.
11. Habecker BA, Klein MG, Cox BC, and Packard BA (2000) Norepinephrine transporter expression in cholinergic sympathetic neurons: differential regulation of membrane and vesicular transporters. Dev Biol 220:85-96.
12. Halliwell B and Gutteridge JM (1984) Free radicals, lipid peroxidation and cell damage. Lancet 2:109519.
13. Hartikka J and Hefti F (1988) Development of septal cholinergic neurons in culture: plating density and glial cells modulate effects of NGF on survival, fiber growth and expression of transmitter-specific enzymes. J Neurosci 8:2967-2985.
14. Hearse DJ and Sutherland FJ (1999) Catecholamines and preconditioning: studies of contraction and function in isolated rat hearts. Am J Physiol 277:H136-H143.
15. Hengartner MO (2000) The biochemistry of apoptosis. Nature (Lond) 407:770-776.
16. Holm PC, Rodriguez FJ, Kresse A, Canals JM, Silos-Santiago I, and Arenas E (2003) Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons. Development 130:3535-3545.
17. Kawamoto JC and Barrett JN (1986) Cryopreservation of primary neurons for tissue culture. Brain Res 384:84-93.
18. Kirkland RA and Franklin JL (2003) Prooxidant effects of NGF withdrawal and MEK inhibition in sympathetic neurons. Antioxid Redox Signal 5:635-639.
19. Knusel B, Beck KD, Winslow JW, Rosenthal A, Burton LE, Widmer HR, Nikolics K, Hefti F (1992) Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J Neurosci 12:4391-4402.
20. Louis JC, Magal E, Burnham P, and Varon S (1993) Cooperative effects of ciliary neurotrophic factor and norepinephrine on tyrosine hydroxylase expression in cultured rat locus coeruleus neurons. Dev Biol 155:1-13.
21. Marien M, Briley M, and Colpaert F (1993) Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol 236:487-489.
22. Marien MR, Colpaert FC, and Rosenquist AC (2004) Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Rev 45:38-78.
23. Matsukawa M, Nakadate K, Ishihara I, and Okado N (2003) Synaptic loss following depletion of noradrenaline and/or serotonin in the rat visual cortex: a quantitative electron microscopic study. Neuroscience 122:627-635.
24. Meier E, Hertz L, and Schousboe A (1991) Neurotransmitters as developmental signals. Neurochem Int 19:1-15.
25. Michel PP and Agid Y (1995) Death of septal cholinergic neurons produced by chronic exposure to glutamate is prevented by the noncompetitive NMDA receptor/ channel antagonist, MK-801: role of nerve growth factor and nitric oxide. J Neurosci Res 40:764-775.
26. Mufson EJ, Ginsberg SD, Ikonomovic MD, and DeKosky ST (2003) Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 26:233-242.
27. Muzykantov VR (2001) Targeting of superoxide dismutase and catalase to vascular endothelium. J Control Release 71:1-21.
28. Pratico D and Sung S (2004) Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimers Dis 6:171-175.
29. Qiu J, Whalen MJ, Lowenstein P, Fiskum G, Fahy B, Darwish R, Aarabi B, Yuan J, and Moskowitz MA (2002) Upregulation of the Fas receptor death-inducing signaling complex after traumatic brain injury in mice and humans. J Neurosci 22:3504-3511.
30. Ricci JE, Munoz-Pinedo C, Fitzgerald P, Bailly-Maitre B, Perkins GA, Yadava N, Scheffler IE, Ellisman MH, and Green DR (2004) Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 117:773-786.
31. Rohn TT, Head E, Nesse WH, Cotman CW, and Cribbs DH (2001) Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol Dis 8:1006-1016.
32. Rommelfanger KS, Weinshenker D, and Miller GW (2004) Reduced MPTP toxicity in noradrenaline transporter knockout mice. J Neurochem 91:1116-1124.
33. Salinas M, Diaz R, Abraham NG, Ruiz de Galarreta CM, and Cuadrado A (2003) Nerve growth factor protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a phosphatidylinositol 3-kinase-dependent manner. J Biol Chem 278:13898-13904.
34. Stites TE, Mitchell AE, and Rucker RB (2000) Physiological importance of quinoenzymes and the o-quinone family of cofactors. J Nutr 130:719-727.
35. Troadec JD, Marien M, Darios F, Hartmann A, Ruberg M, Colpaert F, and Michel PP (2001) Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J Neurochem 79:200-210.
36. 1/2) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol Pharmacol 62:1043-1052.
37. Vauquelin G, Bottari S, Kanarek L, and Strosberg AD (1979) Evidence for essential disulfide bonds in β1-adrenergic receptors of turkey erythrocyte membranes. Inactivation by dithiothreitol. J Biol Chem 254:4462-4469.
38. Zarow C, Lyness SA, Mortimer JA, and Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337-341.
39. Zhang JM, Dix J, Langtimm-Sedlak CJ, Trusk T, Schroeder B, Hoffmann R, Strosberg AD, Winslow JW, and Sieber-Blum M (1997) Neurotrophin-3- and norepinephrine-mediated adrenergic differentiation and the inhibitory action of desipramine and cocaine. J Neurobiol 32:262-280.
40. Zi X, Grasso AW, Kung HJ, and Agarwal R (1998) A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 58:1920-1929.